Welcome to our dedicated page for Adaptimmune Therapeutics plc American Depositary Shares news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics plc American Depositary Shares stock.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on the design, development, and delivery of T-cell therapies to treat cancer. Established in 2008, Adaptimmune has grown from a private entity to one of the top biopharmaceutical IPOs in 2015, and its U.S. operations are headquartered in Philadelphia, PA. Using its proprietary T-cell receptor (TCR) platform, Adaptimmune engineers T-cells to target and destroy cancer cells. This innovative approach has led to the development of a robust pipeline of immuno-oncology product candidates primarily aimed at solid tumors.
The company’s leading programs include afami-cel and lete-cel, both engineered T-cell therapies targeting specific cancer antigens. Afami-cel, targeting MAGE-A4, has shown promising results in treating advanced synovial sarcoma, with the U.S. FDA accepting its Biologics License Application (BLA) for priority review. The anticipated approval and commercial launch of afami-cel in 2024 will mark a significant milestone for Adaptimmune, potentially making it the first engineered T-cell therapy for solid tumors available to patients. Lete-cel, targeting NY-ESO-1, is being evaluated for synovial sarcoma and myxoid round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO trial. Preliminary results indicate a 40% response rate, meeting the primary efficacy endpoint.
Adaptimmune has formed strategic partnerships to advance its pipeline and enhance its manufacturing capabilities. Recent collaborations include agreements with Galapagos to develop next-generation TCR therapies and a $125 million debt financing deal with Hercules Capital, strengthening its financial position.
In addition to its lead programs, Adaptimmune is advancing a broad clinical and preclinical pipeline, including ADP-A2M4CD8 (uza-cel), targeting a range of solid tumors, and several other next-generation and allogeneic T-cell therapies. The company continues to invest in research and development, with plans to expand its platform and address additional cancer indications.
The company’s commitment to transforming cancer treatment is underpinned by a strategy of bringing novel therapies to market efficiently. With over $300 million in funding and strategic plans extending into 2026, Adaptimmune is well-positioned to achieve significant milestones and make substantial impacts in the field of oncology.
Technavio reports that the global gene therapy market is projected to grow by USD 4,613.9 million from 2022 to 2027, at a CAGR of 19.91%. This growth is fueled by increasing special drug designations such as orphan, fast track, and breakthrough designations by regulatory bodies, enhancing market opportunities. The oncology segment will see significant growth due to the unmet demand for cancer treatments. North America is expected to contribute 39% to the market growth, supported by government funding for gene therapy research. However, high treatment costs, ranging from USD 1 million to 3 million, present a major challenge.
The gene therapy market is projected to grow by $4.61 billion from 2023 to 2027, with a CAGR of 19.91%. This growth is attributed to increasing special drug designations, benefits of gene therapy, and rising chronic diseases prevalence.
The market report analyzes key areas including market size, trends, growth drivers, and challenges, covering around 25 vendors. The report segments the market by therapy areas like oncology, CNS, and rare diseases, along with delivery modes and geography.
Key vendors include Adaptimmune Therapeutics (ADAP) and Orchard Therapeutics (ORTX), among others.
The report titled "Global TCR Therapy Market, 2022-2035" outlines significant growth prospects in TCR-based therapies, with an annual growth rate of 51% expected over the next decade. This emerging class of adoptive therapy targets specific tumor markers using genetically modified T-cells, showing efficacy primarily in hematological and solid tumors. The FDA's approval of Kimmtrak for treating metastatic uveal melanoma in January 2022 marks a milestone in the market. The market is projected to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma, with over 90% of therapy candidates being autologous.
ReCode Therapeutics has established a scientific advisory board (SAB) to enhance its genetic medicine pipeline, led by Daniel J. Siegwart. The SAB includes experts such as Rafael Amado and Carrolee Barlow, who bring extensive experience in drug development and delivery technology. This initiative aims to advance their selective organ targeting (SORT) lipid nanoparticle platform and accelerate programs for conditions like primary ciliary dyskinesia and cystic fibrosis to enter clinical stages in 2023.
FAQ
What is the current stock price of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is the market cap of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is Adaptimmune Therapeutics' primary focus?
What are the key programs of Adaptimmune Therapeutics?
What is afami-cel?
When is afami-cel expected to be commercially available?
What is lete-cel?
What are Adaptimmune’s recent strategic collaborations?
Where are Adaptimmune’s U.S. operations based?
What is Adaptimmune’s approach to cancer treatment?
What are the financial projections for Adaptimmune?
How can one get more information about Adaptimmune’s pipeline and operations?
